Myriad Genetics, Inc. (MYGN)
| Market Cap | 344.74M -50.1% |
| Revenue (ttm) | 829.00M -0.3% |
| Net Income | -399.90M |
| EPS | -4.29 |
| Shares Out | 94.45M |
| PE Ratio | n/a |
| Forward PE | 29.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,201,388 |
| Open | 3.580 |
| Previous Close | 3.580 |
| Day's Range | 3.560 - 3.795 |
| 52-Week Range | 3.560 - 8.590 |
| Beta | 1.81 |
| Analysts | Hold |
| Price Target | 6.25 (+71.23%) |
| Earnings Date | May 5, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $6.25, which is an increase of 71.23% from the latest price.
News
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jac...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participa...
Myriad Genetics price target lowered to $6 from $7 at TD Cowen
TD Cowen lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $7 and keeps a Hold rating on the shares. The firm said Q1 results were a…
Myriad Genetics Earnings Call Transcript: Q1 2026
Q1 revenue grew 2% year-over-year to $200.4 million, led by strong hereditary cancer and mental health test growth, while prenatal declined. Gross margin was 68.7%. The company reaffirmed 2026 guidance and expects accelerated growth in the second half, supported by new product launches and an expanded sales force.
Myriad Genetics Earnings release: Q1 2026
Myriad Genetics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Myriad Genetics Slides: Q1 2026
Myriad Genetics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Myriad Genetics Quarterly report: Q1 2026
Myriad Genetics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume ...
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind.
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings con...
Myriad Genetics to deliver six abstracts at AACR 2026
Myriad Genetics (MYGN) announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research, AACR, Annual Meeting 2026. “AACR is one of the…
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, in...
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Healt...
Myriad Genetics Proxy statement: Proxy filing
Myriad Genetics filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Myriad Genetics Proxy statement: Proxy filing
Myriad Genetics filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at...
Myriad Genetics announces FDA approval for MyChoice CDx Test
Myriad Genetics (MYGN) announced that the FDA has approved the MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor from GSK, for patients with advanced ovarian cancer.
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026
Leadership emphasized execution excellence and innovation, with new hires and reorganized teams driving growth in hereditary cancer, GeneSight, and prenatal segments. Product launches and operational improvements support guidance for sequential growth, while ASP stability and risk management remain key priorities.
Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference
Leadership highlighted a renewed strategy focused on cancer care, disciplined growth, and operational excellence. New product launches, strong hereditary cancer test growth, and stabilization in mental health and prenatal segments support a 6% revenue growth target for 2026, with profitability and execution as top priorities.
Myriad Genetics files $200M mixed securities shelf
16:22 EST Myriad Genetics (MYGN) files $200M mixed securities shelf
Myriad Genetics to present six abstracts at ASCO-GU 2026
Myriad Genetics (MYGN) will present new data at the 2026 ASCO-GU conference supporting its Precise MRD Test, Prolaris Prostate Cancer Prognostic Test and MyRisk Hereditary Cancer Tests. These data hig...
Myriad Genetics price target lowered to $6 from $8 at UBS
UBS analyst Lu Li lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $8 and keeps a Neutral rating on the shares.
Myriad Genetics Registration statement: Registration Filing
Myriad Genetics filed a registration statement on February 24, 2026, providing details about a securities offering with the SEC.
Myriad Genetics price target lowered to $6 from $6.50 at Wells Fargo
Wells Fargo lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $6.50 and keeps an Equal Weight rating on the shares. The firm notes Q4 revenue/EBITDA came…